



PATENT

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class RCE, Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

 Jane A. Walker January 3, 2006
Jane A. Walker Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Peyman
Serial No.: 10/631,143
Filed: July 31, 2003
Group Art Unit: 1615
Confirmation No.: 2223
Examiner: Sheikh
Title: **TREATMENT OF OCULAR DISEASE**
Attorney Ref.: PMAN-23

Cincinnati, Ohio 45202

January 3, 2006

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of candor and good faith imposed by 37 C.F.R. §1.56 and means of complying therewith according to 37 C.F.R. §§1.97 and 1.98, the references listed on the attached form PTO-1449 are called to the attention of the United States Patent and Trademark Office in connection with the above-identified patent application.

Applicant has the following co-pending applications disclosing use of one or more macrolides: 10/289,772, 10/667,161, and 10/752,124. The references

submitted in this IDS are or were submitted or cited in applicant's co-pending applications, and are included in the pending application to ensure compliance with applicant's duty of disclosure under 37 C.F.R. §§1.97.

The Examiner is urged to consider the cited references listed on the attached form PTO-1449, and to make an independent decision with respect to materiality.


Applicant does not believe any fee is due with this submission. However, the Examiner is authorized to charge any fee or credit any overpayment to Deposit Account No. 23-3000.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.

Beverly A. Lyman
Beverly A. Lyman, Ph.D.
Reg. No. 41,961

2700 Carew Tower
441 Vine Street
Cincinnati, OH 45202
513 241-2324
513 421-7269 (facsimile)

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))									APPLICANT Gholam Peyman	
									FILING DATE July 31, 2003	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER						ISSUE DATE	PATENTEE		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A	4	0	7	9	0	3	8	03/14/78	Choi et al.	260	47	03/05/76
	A.B	4	0	9	3	7	0	9	06/06/78	Choi et al	424	19	01/28/75
	A.C	4	1	3	1	6	4	8	12/26/78	Choi et al	424	22	03/02/78
	A.D	4	1	3	8	3	4	4	02/06/79	Choi et al	252	1	08/24/77
	A.E	4	1	8	0	6	4	6	12/25/79	Choi et al	528	153	03/03/78
	A.F	4	3	0	4	7	6	7	12/08/81	Heller et al	424	78	05/15/80
	A.G	4	9	4	6	9	3	1	08/07/90	Heller et al	528	320	06/14/89
	A.H	5	2	9	4	6	0	4	03/15/94	Nussenblatt et al.	514	11	12/20/89
	A.I	5	4	1	1	9	5	2	05/1995	Kaswan			
	A.J	5	4	5	7	1	8	2	10/10/95	Wiederrecht et al.	530	402	02/15/94
	A.K	5	7	7	0	6	0	7	06/23/98	Honbo et al.	514	302	07/18/94

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L	JP 07010752 Abstract	01/13/95	JP	A61K	31/365	N/A
	A.M	JP 09315954 Abstract	12/09/97	JP	A61K	9/08	N/A
	A.N	WO 99/22722	05/14/99	PCT	A61K	31/00	N/A
	A.O	AU 17386/88	Unknown	AU	Unknown	Unknown	N/A
	A.P	AU 20350/92	Unknown	AU	Unknown	Unknown	N/A
	A.Q	CN 1333018	01/30/02	CN	A61K	9/06	Abstract only

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

A.R	Algvere et al., <u>Long-term outcome of RPE allografts in non-immunosuppressed patients with AMD</u> , European J of Ophthalmology (1999) 9(3):217-230
A.S	Anderson et al., <u>A Role for Local Inflammation in the Formation of Drusen in the Aging Eye</u> , American Journal of Ophthalmology, Vol. 134, No. 3, September 2002., pp. 411-431
A.T	Aramant et al., <u>Retinal transplanatation</u> , Science & Medicines (2000), 7:20-29

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))									APPLICANT Gholam Peyman	
						FILING DATE July 31, 2003			GROUP 1615	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER							ISSUE DATE	PATENTEE		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A	5	7	7	3	0	1	9	06/30/98	Ashton et al		424	423	09/27/95
	B.B	5	9	5	2	3	7	1	09/14/99	Baker et al.		514	443	10/08/97
	B.C	5	9	6	8	5	4	3	10/19/99	Heller et al.		424	425	12/05/97
	B.D	6	0	0	4	5	6	5	12/21/99	Chiba et al.		424	278.1	09/23/97
	B.E	6	1	7	9	8	1	7	01/30/01	Zhong		604	265	01/28/99
	B.F	6	2	3	9	1	1	3	05/29/01	Dawson et al.		514	29	06/02/99
	B.G	6	2	3	8	7	9	9	05/29/01	Opolski		428	423	02/07/97
	B.H	6	2	5	8	8	5	6	07/10/01	Chamberlain et al		514	912	07/10/01
	B.I	6	3	0	6	4	2	2	10/23/01	Batich et al		424	423	08/03/98
	B.J	6	3	5	0	4	4	2	02/26/02	Garst		424	78.04	05/30/01
	B.K	6	4	1	3	5	3	6	07/02/02	Gibson et al		424	423	08/27/99

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L	CN 1340358	03/20/03	CN	A61K	38/13	Abstract only
	B.M	CN 1456350	11/19/2003	CN	A61K	9/00	Abstract only
	B.N	DE 19810655	09/16/99	DE	A61K	38/13	Abstract only
	B.O	EP 1142566	10/10/01	EP	A61K	9/08	Abstract only
	B.P	JP 10218787	08/18/98	JP	A61K	38/22	Yes
	B.Q	JP 1997030966	02/04/97	JP	A61K	31/365	Yes

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

B.R	Aron-Rosa, <u>Pulsed Nd:YAG lasers in ophthalmology</u> , Nd:YAG Laser Applications pp. 34-48
B.S	Carmo et al., <u>Effect of cyclosporin A on the blood-retinal barrier permeability in streptozotocin-induced diabetes</u> , Mediators of Inflammation (2000), 9(5):243-248
B.T	Chiou, <u>Topical Treatment of Ocular Hypertension, Glaucoma, Ischemic Retinopathy and Age-Related Macular Degeneration with Ophthalmic Formulation of Dopamine Antagonists</u> , U.S. Patent Publication No. US 2003/0069232, published 04/10/03

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))								APPLICANT Gholam Peyman	
		FILING DATE July 31, 2003			GROUP 1615				

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER						ISSUE DATE	PATENTEE		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	C.A	6	4	3	6	9	0	6	Or et al		514	29	04/02/01
	C.B	6	4	4	0	9	4	2	Or et al		514	30	12/22/00
	C.C	6	4	6	2	0	7	1	Castillejos				
	C.D	6	4	6	2	0	2	6	Or et al		514	30	02/16/01
	C.E	6	4	8	2	7	9	9	Tuse et al				
	C.F	6	5	3	4	6	9	3	Fischell et al.		A61F	13/00	01/31/01
	C.G	6	5	9	6	2	9	6	Nelson et al		424	425	08/04/00
	C.H	6	6	1	3	3	5	5	Ng et al		424	462	05/11/01
	C.I	6	6	1	7	3	4	5	Gregory et al		514	395	09/12/00
	C.J	6	6	6	7	3	7	1	Ng et al		525	462	11/14/02
	C.K	6	6	7	0	3	9	8	Edwards et a				

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	C.L	JP 2001064198	03/13/01	JP	A61K	38/22	Yes
	C.M	WO 02/24234	03/28/02	PCT	A61K	48/00	N/A
	C.N	WO 03/051385	06/26/03	PCT	A61K	38/13	Abstract only
	C.O	WO 03/017990	03/06/03	PCT	A61K	31/00	N/A
	C.P	WO 2004/096261	11/11/24	PCT	A61K	38/13	Abstract only
	C.Q	WO 2004/043480	05/27/04	PCT	A61K	38/00	N/A

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C.R	Cicciarelli et al., <u>Pharmacokinetics of subconjunctivally administered cyclosporine A. Local delivery prior to chemotherapy for retinoblastoma</u> , IOVS (3/15/2001), 42(4):S332
C.S	Costantini, LC, et al., <u>Immunophilin Ligands and GDNF Enhance Neurite Branching or Elongation from Developing Dopamine Neurons in Culture</u> , Experimental Neurology 164:60-70 (2000)
C.T	Das et al., <u>The transplantation of human fetal neuroretinal cells in advanced retinitis pigmentosa patients: Results of a long-term safety study</u> , Experimental Neurology (1999), 157:58-68

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))									APPLICANT Gholam Peyman					
		FILING DATE July 31, 2003				GROUP 1615								
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		PATENT NUMBER						ISSUE DATE	PATENTEE		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	D.A	6	6	7	3	8	0	7	01/2004	Sakai et al				
	D.B	6	7	1	3	0	8	1	03/2004	Robinson et al				
	D.C													
	D.D													
	D.E													
	D.F													
	D.G													
	D.H													
	D.I													
	D.J													
	D.K													
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS														
		DOCUMENT NUMBER			PUBLICATION DATE	COUNTRY OR PATENT OFFICE			CLASS	SUBCLASS	TRANSLATION (YES/NO)			
	D.L	WO 2005/030205			04/07/05	PCT			A61K	31/436	N/A			
	D.M	WO 2005/011813			02/10/05	PCT			A61P	27/02	N/A			
	D.N	WO 89/01772			03/02/89	PCT			A61K	9/00	N/A			
	D.O	WO 99/42104			08/26/99	PCT			A61K	31/435	N/A			
	D.P													
	D.Q													
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)														
	D.R	Del Cerro et al., <u>Histologic correlation of human neural retinal transplantation</u> , Invest. Ophthalmology & Visual Science (2000) 41(10): 3142-3148												
	D.S	Dewey, <u>2003 PCO Update: Part 1 - How the square-edged IOL prevents posterior capsular opacification</u> , Cataract & Refractive Surgery Today, September 2003, pp. 20-22												
	D.T	Donnenfeld et al., <u>Cyclosporine provides effective treatment for dry eye</u> , Therapeutic Updates in Ophthalmology, Special Issue, July 1999, pp. 1-3												
EXAMINER								DATE CONSIDERED						
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.														

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))		APPLICANT Gholam Peyman			
		FILING DATE July 31, 2003		GROUP 1615	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	E.A						
	E.B						
	E.C						
	E.D						
	E.E						
	E.F						
	E.G						
	E.H						
	E.I						
	E.J						
	E.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	E.L						
	E.M						
	E.N						
	E.O						
	E.P						
	E.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

E.R	Eneydi et al., <u>Pharmacokinetics and toxicity of an intravitreal device providing sustained release of cyclosporine (CsA) and dexamethasone (DEX)</u> , Investigative Ophthalmology and Visual Science, Vol. 35, No. 4, 1994, p. 1906, and Annual Meeting of the association for Research in Vision and Ophthalmology, Sarasota, FL, USA, May 1-6, 1994 abstract
E.S	Enyedi et al., <u>An intravitreal device providing sustained release of cyclosporine and dexamethasone</u> , Current Eye Research, May 1996, Vol. 15, No. 5, pp. 549-557
E.T	Garweg et al., <u>Therapy of Goldmann-Favre's Vitreo-Retinal Degeneration with Cyclosporin A and Bromocriptine</u> , Klinische Monatsblatter fur Augenheilkunde, Vol. 199, No. 3, September 1991, pp. 199-205

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))		APPLICANT Gholam Peyman			
		FILING DATE July 31, 2003		GROUP 1615	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER		ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	F.A							
	F.B							
	F.C							
	F.D							
	F.E							
	F.F							
	F.G							
	F.H							
	F.I							
	F.J							
	F.K							

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	F.L						
	F.M						
	F.N						
	F.O						
	F.P						
	F.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	F.R	Gilbard, <u>EW Interview: Electrolyte balance is key to dry-eye product's success</u> , EyeWorld, February 1999, pp. 20ff
	F.S	Grisolano et al., <u>Retinal Toxicity Study of Intravitreal Cyclosporin</u> , Ophthalmic Surgery, March 1986, 17:155-156
	F.T	Hageman et al., <u>Diagnostics and Therapeutics for Macular Degeneration-Related Disorders</u> , U.S. Patent Application Publication No. US 2--2/0015957, published 02/07/02

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))		APPLICANT Gholam Peyman			
		FILING DATE July 31, 2003	GROUP 1615		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	G.A						
	G.B						
	G.C						
	G.D						
	G.E						
	G.F						
	G.G						
	G.H						
	G.I						
	G.J						
	G.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	G.L						
	G.M						
	G.N						
	G.O						
	G.P						
	G.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	G.R	Jiang et al, <u>Corneal electroretinographic function rescued by normal retinal pigment epithelial grafts in retinal degenerative Royal College of Surgeons rats</u> , Invest. Ophthalmology & Visual Science (1994). 35(13):4300-4308
	G.S	Karacorlu et al, <u>Lack of toxicity of intravitreally administered interferon Alpha-2a</u> , Ophthalmic Surgery (1999) 23:833-835
	G.T	Keep et al, <u>Introduction: Immunosuppressants as Neuroprotective Agents, Immunosuppressant Analogs in Neuroprotection, Part I: Immunosuppressants, Neurologic Disorders, and Neuroprotection</u> , Ed. Borlongan & Sanberg, Humana Press Inc., Totowa NJ, pp.3-32

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))		APPLICANT Gholam Peyman			
		FILING DATE July 31, 2003		GROUP 1615	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	H.A						
	H.B						
	H.C						
	H.D						
	H.E						
	H.F						
	H.G						
	H.H						
	H.I						
	H.J						
	H.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	H.L						
	H.M						
	H.N						
	H.O						
	H.P						
	H.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

H.R	Kiryu et al., <u>In Vivo Evaluation of the Inhibitory Effects of Tacrolimus (FK506) on Leukocyte Accumulation During Retinal Ischemia Reperfusion Injury</u> , Poster Presentation 1247-B128
H.S	Lai et al., <u>Local immunosuppression prolongs survival of RPE xenografts labeled by retroviral gene transfer</u> , IOVS (9/2000) 41(10):3134-3141
H.T	Lallemand et al., <u>Cyclosporine A delivery to the eye: A pharmaceutical challenge</u> , European Journal of Pharmaceutics and Biopharmaceutics, 56 (2003), pp. 307-318

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))		APPLICANT Gholam Peyman			
		FILING DATE July 31, 2003	GROUP 1615		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	I.A						
	I.B						
	I.C						
	I.D						
	I.E						
	I.F						
	I.G						
	I.H						
	I.I						
	I.J						
	I.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	I.L						
	I.M						
	I.N						
	I.O						
	I.P						
	I.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	I.R	Lipner, <u>Dry Eye 101: Developing etiologies and treatments for this widespread syndrome</u> , EyeWorld, February 1999, pp. 19ff
	I.S	Lipper et al., <u>Recent therapeutic advances in dermatology</u> , JAMA, Vol. 283, No. 2, January 12, 2000, pp. 175-177
	I.T	Lopez et al., <u>Transplanted retinal pigment epithelium modifies the retinal degeneration in the RCS</u> , Invest. Ophthalmology & Visual Science (1989), 30:586-588

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))		APPLICANT Gholam Peyman			
		FILING DATE July 31, 2003	GROUP 1615		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	J.A						
	J.B						
	J.C						
	J.D						
	J.E						
	J.F						
	J.G						
	J.H						
	J.I						
	J.J						
	J.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	J.L						
	J.M						
	J.N						
	J.O						
	J.P						
	J.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

J.R	Lund, et al., <u>Subretinal transplantation of genetically modified human cell lines attenuates loss of visual function in dystrophic rats</u> , PNCS (2001), 98(17): 9942-9947
J.S	Martin DF et al., <u>Synergistic Effect of Rapamycin and Cyclosporin A in the Treatment of Experimental Autoimmune Uveoretinitis</u> , The Journal of Immunology, 1995, 154:922-927
J.T	Nicoletti et al., <u>The effects of deoxyspergualin on the development of diabetes in diabetes-prone BB rats</u> , Scandinavian Journal of Immunology (1992) 36(3):415-420

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))					APPLICANT Gholam Peyman			
					FILING DATE July 31, 2003	GROUP 1615		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	K.A							
	K.B							
	K.C							
	K.D							
	K.E							
	K.F							
	K.G							
	K.H							
	K.I							
	K.J							
	K.K							
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS								
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE		CLASS	SUBCLASS	TRANSLATION (YES/NO)
	K.L							
	K.M							
	K.N							
	K.O							
	K.P							
	K.Q							
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)								
	K.R	Passos et al, <u>Ocular Toxicity of Intravitreal Tacrolimus</u> , Ophthalmic Surgery and Lasers, March/April 2002, Vol. 22, No. 2, pp. 140-144						
	K.S	PCT, <u>International Search Report</u> , PCT/US03/28315, mailed 06/15/04, 6 pages						
	K.T	Peyman et al., <u>Intravitreal Surgery</u> , Principles and Practice, 2nd Edition, 1994, Ppletton & Lange, Connecticut, pp. 443-452						
EXAMINER				DATE CONSIDERED				
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.								

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))				APPLICANT Gholam Peyman	
				FILING DATE July 31, 2003	GROUP 1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER		ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	L.A							
	L.B							
	L.C							
	L.D							
	L.E							
	L.F							
	L.G							
	L.H							
	L.I							
	L.J							
	L.K							

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	L.L						
	L.M						
	L.N						
	L.O						
	L.P						
	L.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	L.R	Peyman et al., <u>Keratitis (Noninfectious)</u> , Principles and Practice of Ophthalmology, W.B. Saunders Company, 1980, pp. 446-449
	L.S	Peyman et al., <u>Intravitreal drug therapy</u> , Japanese Journal of Ophthalmology (1989), 33(4): 392-404
	L.T	Peyman, <u>Treatment of Ocular Disease</u> , U.S. Application Publication No. 2004/0092435, published 05/13/04, Serial No. 10/289,772, filed 11/07/02

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))					APPLICANT Gholam Peyman	
					FILING DATE July 31, 2003	GROUP 1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER		ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	M.A							
	M.B							
	M.C							
	M.D							
	M.E							
	M.F							
	M.G							
	M.H							
	M.I							
	M.J							
	M.K							

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	M.L						
	M.M						
	M.N						
	M.O						
	M.P						
	M.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	M.R	Peyman, <u>Treatment of Ocular Disease</u> , U.S. Application Publication No. 2005/0025810, published 02/03/05, Serial No. 10/631,143, filed 07/31/03
	M.S	Peyman, <u>Ocular Solutions</u> , U.S. Application Publication No. 2005/0063997, published 03/24/05, Serial No. 10/752,124, filed 01/06/04
	M.T	Peyman, <u>Ocular Solutions</u> , U.S. Application Publication No. 2005/0063996, published 03/24/05, Serial No. 10/667,161, filed 09/19/03,

EXAMINER _____ DATE CONSIDERED _____

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))					APPLICANT Gholam Peyman	
					FILING DATE July 31, 2003	GROUP 1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	N.A						
	N.B						
	N.C						
	N.D						
	N.E						
	N.F						
	N.G						
	N.H						
	N.I						
	N.J						
	N.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	N.L						
	N.M						
	N.N						
	N.O						
	N.P						
	N.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	N.R	Peyman, <u>Pupillary Membranes: Nd'YAG Capsulotomy, Intravitreal Surgery</u> , Norwalk CT, Appleton & Lange, 1994, pp. 253-257
	N.S	Peyman et al., <u>Implantation of a sustained-release ganciclovir implant</u> , Vitreoretinal Surgical Techniques, Martin Dunitz Ltd., 2001, Chapter 45, pp. 521-531
	N.T	Schonfield and Kirst, <u>Macrolide Antibiotics</u> , Birkhauser, Basil, Switzerland, 2002, pp. 1-36

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))				APPLICANT Gholam Peyman	
				FILING DATE July 31, 2003	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER		ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	O.A							
	O.B							
	O.C							
	O.D							
	O.E							
	O.F							
	O.G							
	O.H							
	O.I							
	O.J							
	O.K							

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	O.L						
	O.M						
	O.N						
	O.O						
	O.P						
	O.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	O.R	Shen et al., <u>Combined effect of cyclosporine and sirolimus on improving the longevity of recombinant adenovirus-mediated transgene expression in the retina</u> , Archives of Ophthalmology (7/2001), 119(7): 1033-1043
	O.S	Stosic-Grujicic et al, <u>Leflunomide protects mice from multiple low dose streptozotocin (MLD-SA)-induced insulitis and diabetes</u> , Clinical & Experimental Immunology (1999) 117(1):44-50
	O.T	Ueno, <u>Composition for Topical Administration</u> , U.S. Patent Application Publication No. US2003/0044452 published 03/06/03, Serial No. 10/187,013, filed 07/02/02

EXAMINER _____ DATE CONSIDERED _____

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. PMAN/23	SERIAL NO. 10/631,143
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))		APPLICANT Gholam Peyman			
		FILING DATE July 31, 2003	GROUP 1615		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	P.A						
	P.B						
	P.C						
	P.D						
	P.E						
	P.F						
	P.G						
	P.H						
	P.I						
	P.J						
	P.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	P.L						
	P.M						
	P.N						
	P.O						
	P.P						
	P.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

P.R	Wakelee-Lynch, <u>Interferon may offer first drug therapy for diabetic retinopathy</u> , Diabetes Care (1992), 15(2):300-301
P.S	Wise, <u>Handbook of Pharmaceutical Controlled Release Technology</u> , Marcel Dekker, New York, 2000
P.T	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Client/Matter: PMAN-23

WHE Docket No.: 60861

The stamp of the Patent Office hereon, may be taken as acknowledging the receipt, on the date stamped, of the following items in the captioned case:

Inventor(s): Peyman
Serial No.: 10/631,143
Filing Date: July 31, 2003
Title: TREATMENT OF OCULAR DISEASE
Conf.No.: 2223
Enclosures: Supplemental Information Disclosure Statement; copies of 41 references; Certificate of Mailing; Return postcard

Beverly A. Lyman, Esquire (126)
WOOD, HERRON & EVANS, L.L.P.

November 22, 2005